Immune-Related Colitis Induced by Camrelizumab: A Case Report

被引：3

作者：

Cheng, Sheng ^{[1
]}

Yang, Yun ^{[2
]}

Yu, Junxian ^{[1
]}

Chen, Wei ^{[1
]}

Li, Xingang ^{[1
,3
]}

机构：

[1] Capital Med Univ, Beijing Friendship Hosp, Dept Pharm, Beijing, Peoples R China

[2] Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing, Peoples R China

[3] Capital Med Univ, Beijing Friendship Hosp, Beijing 100050, Peoples R China

来源：

JOURNAL OF INFLAMMATION RESEARCH | 2023年 / 16卷

关键词：

immune checkpoint inhibitor; colitis; anti-programmed cell death blockade; immune-related colitis; camrelizumab; MANAGEMENT;

D O I：

10.2147/JIR.S405023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In recent years, immunotherapy has become a major research focus in the field of cancer treatment. Because of its good efficacy and lasting immune response, immune checkpoint inhibitors have benefited the long-term survival of many types of cancer patients. However, overactivation of the immune system may attack normal organs and cause a series of immune related adverse reactions. Among them, due to the high incidence of immune-related colitis, it deserves special attention. Camrelizumab is a programmed cell death 1 (PD-1) inhibitor that was developed by Jiangsu Hengrui Medicine Company. We reported the clinical data of a case of hepatocellular carcinoma with immune-related colitis after treatment with camrelizumab. A 63-year-old man with hepatocellular carcinoma developed diarrhea and hematochezia after receiving 4 cycles of camrelizumab. Endoscopy showed multiple flake congestion and edema in the terminal ileum and total colon mucosa with bright red surface. Pathological evaluation showed chronic inflammation of colonic mucosa. After giving 0.25g bid of enteric-coated sulfasalazine tablets orally for 6 weeks, his colitis improved. Camrelizumab can induce immune-related colitis. Sulfasalazine could be used to reduce adverse reactions of glucocorticoids.

引用

页码：1727 / 1731

页数：5

共 15 条

[1] Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease [J].

Abu-Sbeih, Hamzah ;

Wang, Yinghong .

INFLAMMATORY BOWEL DISEASES, 2020, 26 (05) :662-668

[2] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[3] Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials [J].

Fang, Wenfeng ;

Yang, Yunpeng ;

Ma, Yuxiang ;

Hong, Shaodong ;

Lin, Lizhu ;

He, Xiaohui ;

Xiong, Jianping ;

Li, Ping ;

Zhao, Hongyun ;

Huang, Yan ;

Zhang, Yang ;

Chen, Likun ;

Zhou, Ningning ;

Zhao, Yuanyuan ;

Hou, Xue ;

Yang, Qing ;

Zhang, Li .

LANCET ONCOLOGY, 2018, 19 (10) :1338-1350

[4] Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].

Haanen, J. ;

Obeid, M. ;

Spain, L. ;

Carbonnel, F. ;

Wang, Y. ;

Robert, C. ;

Lyon, A. R. ;

Wick, W. ;

Kostine, M. ;

Peters, S. ;

Jordan, K. ;

Larkin, J. .

ANNALS OF ONCOLOGY, 2022, 33 (12) :1217-1238

[5] Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial [J].

Qin, Shukui ;

Ren, Zhenggang ;

Meng, Zhiqiang ;

Chen, Zhendong ;

Chai, Xiaoli ;

Xiong, Jianping ;

Bai, Yuxian ;

Yang, Lin ;

Zhu, Hong ;

Fang, Weijia ;

Lin, Xiaoyan ;

Chen, Xiaoming ;

Li, Enxiao ;

Wang, Linna ;

Chen, Chunxia ;

Zou, Jianjun .

LANCET ONCOLOGY, 2020, 21 (04) :571-580

[6] The diverse functions of the PD1 inhibitory pathway [J].

Sharpe, Arlene H. ;

Pauken, Kristen E. .

NATURE REVIEWS IMMUNOLOGY, 2018, 18 (03) :153-167

[7] Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer [J].

Simonaggio, Audrey ;

Michot, Jean Marie ;

Voisin, Anne Laure ;

Le Pavec, Jerome ;

Collins, Michael ;

Lallart, Audrey ;

Cengizalp, Geoffray ;

Vozy, Aurore ;

Laparra, Ariane ;

Varga, Andrea ;

Hollebecque, Antoine ;

Champiat, Stephane ;

Marabelle, Aurelien ;

Massard, Christophe ;

Lambotte, Olivier .

JAMA ONCOLOGY, 2019, 5 (09) :1310-1317

[8] The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis [J].

Tandon, Parul ;

Bourassa-Blanchette, Samuel ;

Bishay, Kirles ;

Parlow, Simon ;

Laurie, Scott A. ;

McCurdy, Jeffrey D. .

JOURNAL OF IMMUNOTHERAPY, 2018, 41 (03) :101-108

[9] Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management [J].

Tang, Liansha ;

Wang, Jialing ;

Lin, Nan ;

Zhou, Yuwen ;

He, Wenbo ;

Liu, Jiyan ;

Ma, Xuelei .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[10] Review of cancer treatment with immune checkpoint inhibitors [J].

Thallinger, Christiane ;

Fuereder, Thorsten ;

Preusser, Matthias ;

Heller, Gerwin ;

Muellauer, Leonhard ;

Hoeller, Christoph ;

Prosch, Helmut ;

Frank, Natalija ;

Swierzewski, Rafal ;

Berger, Walter ;

Jaeger, Ulrich ;

Zielinski, Christoph .

WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 (3-4) :85-91

← 1 2 →